Believe me, it was on the tip of my tongue when he mentioned to .6 dose for B. "Why not .7?" , but alas I did not ask. Leo and Dr. J went on at length to describe how most other antibiotics are reformulations of other existing ones and that means their is more risk with B because it is so different/new it makes me think they are leaning towards safety vs a couple % on the efficacy side. I think their goal is to just get the drug approved.

Regarding suggestions to Leo, he made special note to thank shareholders for their suggestions and noted that they are considering the pump based off shareholder feedback. He said he appreciates them and to keep them coming.